Daxor Corporation DXR PHARMA
Company Overview
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Why Investors Should Care
Trades at a P/E of 8.4, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2011 Revenue of $1.45M (-8.4% YoY); net profit $-7.19M.
- Trailing 12 Months Year-on-year growth — revenue +25.5%, earnings +329.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -8.42% |
| 1 Year: | 25.50% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 329.30% |
Stock Price Performance
| 1 Year: | -16.14% |
| 6 Months: | -9.76% |
| 3 Months: | -9.40% |
| 1 Month: | -18.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.79 · Oversold
P/E of 8.41 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -8.4% CAGR over 5 years.
- Trading 37.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DXR Daxor Corporation PHARMA | 9.25 | 8.41 | $54.00M | 0.00% | -15.87% | 14.24% | -8.42% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2010 | Sep 2011 |
|---|---|---|
| Revenue | 453.28K | 340.91K |
| Gross Profit | 267.54K | 191.53K |
| Operating Income | -1.28M | -1.26M |
| Net Income | 2.60M | -4.18M |
| R&D Expense | 694.73K | 637.05K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 |
|---|---|---|
| Revenue | 1.58M | 1.45M |
| Gross Profit | 851.61K | 793.83K |
| Operating Income | -5.66M | -5.79M |
| Net Income | 4.97M | -7.19M |
| R&D Expense | 3.04M | 2.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 |
|---|---|---|---|
| Total Assets | - | 91.20M | 85.72M |
| Total Equity | 47.63M | 47.00M | 36.22M |
| Cash & Equivalents | 277.09K | 57.74K | 59.62K |
| Total Liabilities | - | 44.20M | 49.51M |
| Current Liabilities | - | 43.90M | 49.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 |
|---|---|---|
| Operating Cash Flow | -5.69M | -6.51M |
| Investing Cash Flow | 9.40M | -11.39M |
| Financing Cash Flow | -3.93M | 17.90M |
| Capital Expenditure | -324.71K | -123.15K |
| Free Cash Flow | -6.01M | -6.63M |
| Dividends Paid | 4.23M | 1.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 |
|---|---|---|
| Gross Margin % | 53.9% | 54.9% |
| Operating Margin % | -358.3% | -400.1% |
| Net Margin % | 314.6% | -496.8% |
| ROE % | 10.6% | -19.8% |
| ROCE % | -12.0% | -15.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Thompson, Siegel & Walmsley LLC | 4.14% | 241.77K | $2.52M |
| 2 | Vanguard Capital Management LLC | 0.84% | 48.83K | $508.33K |
| 3 | Aristides Capital, LLC | 0.71% | 41.69K | $433.98K |
| 4 | Renaissance Technologies, LLC | 0.50% | 29.42K | $306.27K |
| 5 | Susquehanna International Group, LLP | 0.46% | 27.13K | $282.43K |
| 6 | Crescent Grove Advisors, Llc | 0.21% | 12.42K | $129.32K |
| 7 | Nano Cap New Millennium Growth Fund L P | 0.21% | 12.50K | $130.12K |
| 8 | SBI Securities Co., Ltd. | 0.05% | 3.13K | $32.59K |
| 9 | Morgan Stanley | 0.05% | 3.09K | $32.13K |
| 10 | Vanguard Fiduciary Trust Co | 0.02% | 1.04K | $10.79K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DXR
(DXR) Strategic Equity Report (DXR:CA) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPWThlUmVRMzJ0RlctMUphR2Y2VzhRbXB2dS1hN3BrQ20zU2ViYnNvTUxEVlk1SDRBbS03UTNocjNQdE5mSEZFWF9JVGE5Qk1HVEF6U05mOW1XMjhIME9vOVQyM2dzd2pCQUtNYnFUSU5lT3I1Q0p0cWprMHVHaTVUMTdGZHo3bEVqYTJydD…
A blood-volume analyzer uses 50% less sample. Daxor will demonstrate it in Denver. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdGtyZEpuVTNJQ3pkS3dSTVR1RWtBV2sya3NCTmRTSmhYbU42WXFMRmZhcXdtMjN6UDZuNDRNSk90U21VeHNfeDZkVUhUOW1OR011WjdIcHFrOXVRWVlsRzNUdHp2NnFWNTlBX3hKb3VkUTRoSC11LUt4Q0hKLUVySTNpZm1MbjRQUU9JM0…
DXR N-CSR/A & SEC Filings - Yahoo Finance - Yahoo
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5QeHNlMnFheHJmZUVVLVdYR2ctWGxpNC14cGdSWlF5MXU5a1dKcG9vSHR1V29INFVWR1dKMi1ZN2lFS1dXLXU4b0Q4NlhQY21uLTl5ajdLMkR4T3dSYUtBS1ppM3BVQnBLTmRhdDM4MU9oVVdPQU90dmFR?oc=5" target="_blank">DXR…
A lab test measures blood, red cells and plasma directly for kidney care - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPWF9kTVpUSGRhb01hZlFHMG5jeHhILWQxUGJYTDFyQjh1M05kc09qUW1fQ2h3SE9uNlBFbExENnFCaDFWUFpqSzNHS0d5N0E1cUprM1hhYl9TdENSVlU3WlNENUE2UzRBTmpwMUh4Qzlta0NlSmtESEtqdGNCT2NtVTV5aWwyVWVCQ0oyal…
Daxor Corporation (DXR) Holds Steady at $10.41 as Shares Consolidate Between Key Technical Levels - Common Gap - siam.in
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZDVYZEV0bVNpdHBKQVh1X3N6NFN3eU9FYVZVYzJZUEZpTmlMc3BaSkZzTjhDU2FId1c0ODdxZ2xyX1RvVVVJT1g5bl9lYk5vcjRKUUxaUHdWVFBkVFJTZ2NPcVRxcnFyeTlVQnB4RVUtekdOSUZIbkhTczItZFIzX2NQckxnVEUyV1cyUF…
Daxor Corporation (DXR) Advances 2.72% to $10.03 on Renewed Interest in Blood Volume Diagnostics - ETF NAV Deviation - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxOY2ItZHdHUkhvUml6aGpFQWQxbUZmYUhNUlNzX1MzQmtxS0YycmRjSzJGSkJDYnJDUzdYcHBCcUhKaFZabjQ3VDNIb0gyUGdLcU4xVEI3eEFTV0JXTnJtSzV2cDRGRUIzSVA5UEIta0c3UlFkb2pMV1N1ZjVka0FFNW9zMVo1c0pMaDJ2ck…
DXR — Frequently Asked Questions
What is the current share price of Daxor Corporation (DXR)?
As of 2026-10-23 16:27 PDT, Daxor Corporation (DXR) trades at $9.25 on NasdaqCM. Its 52-week range is $8.87 to $14.75.
What is the market capitalisation of DXR?
Daxor Corporation (DXR) has a market capitalisation of $54.00M on NasdaqCM.
What is the P/E ratio of DXR?
DXR trades at a trailing price-to-earnings (P/E) ratio of 8.41. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.17.
What is the return on equity (ROE) of DXR?
DXR has a return on equity (ROE) of 14.24%. Its return on capital employed (ROCE) is -15.87%.
Is DXR a good stock to buy?
This page provides a data-driven analysis of Daxor Corporation (DXR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.